BCL10 antibody [BL10/411]

GeneTex

BCL10 antibody [BL10/411]

9

WB: 1-2microg/ml. IHC-P: 1-2microg/ml for 30 minutes at RT. FACS: 1-2microg/106 cells. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.

Flow Cytometry, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Research Use Only

Monoclonal

BL10/411

0.2 mg/ml

Unconjugated

BCL10

BCL10 immune signaling adaptor

CARMEN, CIPER, CLAP, IMD37, c-E10, mE10, B-cell lymphoma/leukemia 10, B cell CLL/lymphoma 10, CARD containing molecule enhancing NF-kB, CARD-containing apoptotic signaling protein, CARD-containing molecule enhancing NF-kappa-B, CARD-containing proapoptotic protein, CED-3/ICH-1 prodomain homologous E10-like regulator, cCARMEN, caspase-recruiting domain-containing protein, cellular homolog of vCARMEN, cellular-E10, hCLAP, mammalian CARD-containing adapter molecule E10

Mouse

IgG1

B-cell lymphoma/leukemia 10

This gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2016]

-20°C or -80°C,2°C to 8°C

12352203